Globus Medical Earnings Call Transcripts
Fiscal Year 2025
-
Delivered record 2025 results with 16.7% revenue growth and 30.8% non-GAAP EPS growth, driven by strong U.S. spine, enabling tech, and trauma segments. 2026 guidance raised for EPS, with continued margin expansion, robust product launches, and successful integration of NuVasive and Nevro.
-
Q3 2025 saw record revenue, EPS, and free cash flow, led by strong U.S. spine and trauma growth, with Nevro integration ahead of schedule and accretive to earnings. Guidance for 2025 was raised for both revenue and EPS, reflecting confidence in continued profitable growth.
-
Q2 2025 saw 18.4% revenue growth and 14.1% non-GAAP EPS growth, driven by strong U.S. spine and trauma performance, successful Nevro integration, and robust product innovation. Guidance for 2025 is reaffirmed, with continued focus on operational excellence and market share gains.
-
Q1 2025 saw flat sales and a 1.4% revenue decline, but profitability and free cash flow hit record highs. The company returned to debt-free status, completed the Nevro acquisition, and reaffirmed 2025 sales guidance, with Q2 already showing recovery as supply chain issues ease.
-
The conference highlighted successful integration with NuVasive, robust financial performance, and a strong innovation pipeline, including robotics and trauma solutions. Strategic acquisitions and operational synergies are expected to drive growth, with a focus on expanding enabling technologies and international reach.
Fiscal Year 2024
-
Record revenue and EPS growth driven by strong U.S. and international spine sales, robust enabling technology placements, and successful integration of NuVasive. Announced Nevro acquisition to expand into neuromodulation, with 2025 guidance reflecting continued growth and margin improvement.
-
Q3 2024 delivered record sales, EPS, and free cash flow, driven by strong U.S. and international spine growth, successful integration of NuVasive, and robust product launches. Guidance for 2024 was raised, with synergies and operational improvements ahead of schedule.
-
Q2 2024 saw 116% revenue growth to $630M, driven by the NuVasive merger and strong organic gains. Non-GAAP EPS rose 20% to $0.75, with robust product launches and record robotic placements. 2024 guidance was raised, reflecting confidence in continued integration and synergy realization.